-
公开(公告)号:US20090098115A1
公开(公告)日:2009-04-16
申请号:US11875251
申请日:2007-10-19
IPC分类号: A61K39/395 , C12N5/06 , A01K67/027 , A61K38/02 , C12Q1/02
CPC分类号: A01K67/0271 , A01K2217/15 , A01K2227/105 , A01K2267/0331 , A61K31/565 , A61K39/39558 , A61K45/06 , A61K47/6803 , A61K47/6855 , A61K2039/505 , A61K2039/545 , C07K16/32 , G01N33/5011 , A61K2300/00
摘要: The present invention concerns cell lines and animal models of HER2-expressing tumors. In particular, the invention concerns cell lines and animal models of HER2-expressing tumors not responding or responding poorly to treatment with trastuzumab (HERCEPTIN®, Genentech, Inc.). The animal models and cell lines of the invention are useful for evaluating the efficacy of various therapeutic approaches for the treatment of such tumors.
摘要翻译: 本发明涉及表达HER2的肿瘤的细胞系和动物模型。 特别地,本发明涉及对曲妥珠单抗(Genentech,Inc。)治疗无反应或反应不良的HER2表达肿瘤的细胞系和动物模型。 本发明的动物模型和细胞系可用于评估用于治疗这种肿瘤的各种治疗方法的功效。